XML 65 R46.htm IDEA: XBRL DOCUMENT v3.22.4
License and Asset Purchase Agreements - Additional Information - Menarini License Agreement (Detail) - USD ($)
$ in Millions
1 Months Ended 48 Months Ended
Dec. 31, 2021
Dec. 31, 2025
Dec. 31, 2020
Jun. 30, 2020
May 23, 2018
Menarini License Agreement [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments $ 75.0        
Antengene Therapeutics [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments     $ 13.7    
License Agreement Terms [Member] | Menarini License Agreement [Member] | Global development of the Product | Future [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Documented Expenses   25.00%      
Maximum Documented Expenses   $ 15.0      
Maximum [Member] | License Agreement Terms [Member] | Menarini License Agreement [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Milestone Payment 202.5        
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Menarini License Agreement [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments 75.0        
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Menarini License Agreement [Member] | Transaction Price at Contract Inception [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments $ 75.0        
Up-front Payment Arrangement [Member] | License Agreement Terms [Member] | Antengene Therapeutics [Member]          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments       $ 11.7 $ 11.7